COMMUNIQUÉS West-GlobeNewswire

-
Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results
14/11/2024 -
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
14/11/2024 -
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
14/11/2024 -
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
14/11/2024 -
TFF Pharmaceuticals Announces It Will Wind Down Operations
14/11/2024 -
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14/11/2024 -
Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability
14/11/2024 -
Panbela Provides Business Update and Reports Q3 2024 Financial Results
14/11/2024 -
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14/11/2024 -
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
14/11/2024 -
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14/11/2024 -
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14/11/2024 -
Invizyne Technologies Announces Closing of Initial Public Offering
14/11/2024 -
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
14/11/2024 -
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
14/11/2024 -
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
14/11/2024 -
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
14/11/2024 -
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
14/11/2024 -
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
14/11/2024
Pages